Roche Extends Tender Offer Period in Pending $4.3-Billion Acquisition of Spark Therapeutics
Roche has extended its tender offer period relating to its pending $4.3-billion acquisition of Spark Therapeutics, a Philadelphia-based gene-therapy company, from July 31, 2019 to September 3, 2019.
Roche extended the offer period to provide additional time for the US Federal Trade Commission (FTC) and the UK Competition and Markets Authority to complete their previously disclosed reviews of Roche’s pending acquisition of Spark.
In June 2019, Roche and Spark received a request for additional information from the FTC regarding Roche’s pending $4.3-billion acquisition of Spark. Additionally, the UK Competition and Markets Authority opened an investigation to evaluate whether it had jurisdictional authority to review the transaction.